Stephens & Co. Upgrades Glaukos to Overweight, Raises Price Target to $68
Stephens & Co. analyst Chris Cooley upgrades Glaukos (NYSE:GKOS) from Equal-Weight to Overweight and raises the price target from $60 to $68.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 11)
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 6)
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 4)
Glaukos Corporation Received FDA Orphan Drug Designation on Tuesday for riboflavin 5′-phosphate sodium for Treatment of Corneal Ulcers
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=812721
Glaukos Files Pre-Market Application For Intraocular Pressure Device
Glaukos Corp (NYSE:GKOS) has submitted a supplemental premarket approval (PMA) application to the FDA for its iStent infinite Trabecular Micro-Bypass System.…
Glaukos Announces Submission of Supplemental Pre-Market Approval Application for iStent infinite
Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has
Glaukos Guided Below Consensus After Q2 Earnings; Analysts Cut Price Target
Glaukos Corporation (NYSE:GKOS) posted a second-quarter adjusted EPS loss of $(0.11), ahead of $(0.28) consensus, and better than $(0.61) a year…
Stephens & Co. Maintains Equal-Weight on Glaukos, Lowers Price Target to $60
Stephens & Co. analyst Chris Cooley maintains Glaukos (NYSE:GKOS) with a Equal-Weight and lowers the price target from $70 to $60.